The efficacy of T790M mutation testing in liquid biopsy—Real clinic data

Osimertnib is still widely used in the treatment of NSCLC patients who have previously received erlotinib, gefitinib or afatinib and have developed resistance to these drugs mediated by the T790M mutation in exon 20 of EGFR gene. We assessed the results of T790M mutation testing in liquid biopsy by...

Descripción completa

Detalles Bibliográficos
Autores principales: Krawczyk, Paweł, Grzycka-Kowalczyk, Luiza, Błach, Justyna, Reszka, Katarzyna, Chmielewska, Izabela, Kieszko, Robert, Wójcik-Superczyńska, Magdalena, Szczyrek, Michał, Jankowski, Tomasz, Milanowski, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075651/
https://www.ncbi.nlm.nih.gov/pubmed/35522668
http://dx.doi.org/10.1371/journal.pone.0267846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075651/
https://www.ncbi.nlm.nih.gov/pubmed/35522668
http://dx.doi.org/10.1371/journal.pone.0267846

Ejemplares similares